Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction

Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition

Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to Evaluate...